- Home
- XFOR vs PETS Comparison
XFOR vs PETS Comparison
Compare XFOR & PETS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- XFOR
- PETS
- Stock Information
- Founded
- XFOR 2014
- PETS 1996
- Country
- XFOR United States
- PETS United States
- Employees
- XFOR N/A
- PETS N/A
- Industry
- XFOR Biotechnology: Biological Products (No Diagnostic Substances)
- PETS Retail-Drug Stores and Proprietary Stores
- Sector
- XFOR Health Care
- PETS Consumer Staples
- Exchange
- XFOR Nasdaq
- PETS Nasdaq
- Market Cap
- XFOR 84.3M
- PETS 70.4M
- IPO Year
- XFOR N/A
- PETS N/A
- Fundamental
- Price
- XFOR $3.64
- PETS $3.02
- Analyst Decision
- XFOR Strong Buy
- PETS Sell
- Analyst Count
- XFOR 3
- PETS 1
- Target Price
- XFOR $34.17
- PETS $3.20
- AVG Volume (30 Days)
- XFOR 10.6M
- PETS 108.6K
- Earning Date
- XFOR 08-08-2025
- PETS 11-03-2025
- Dividend Yield
- XFOR N/A
- PETS N/A
- EPS Growth
- XFOR N/A
- PETS N/A
- EPS
- XFOR N/A
- PETS 0.02
- Revenue
- XFOR $32,774,000.00
- PETS $247,010,000.00
- Revenue This Year
- XFOR $1,313.84
- PETS N/A
- Revenue Next Year
- XFOR N/A
- PETS N/A
- P/E Ratio
- XFOR N/A
- PETS $177.86
- Revenue Growth
- XFOR 5721.31
- PETS N/A
- 52 Week Low
- XFOR $1.35
- PETS $2.81
- 52 Week High
- XFOR $26.83
- PETS $6.85
- Technical
- Relative Strength Index (RSI)
- XFOR 51.62
- PETS 42.37
- Support Level
- XFOR $3.57
- PETS $3.01
- Resistance Level
- XFOR $4.83
- PETS $3.26
- Average True Range (ATR)
- XFOR 0.55
- PETS 0.11
- MACD
- XFOR -0.05
- PETS 0.00
- Stochastic Oscillator
- XFOR 26.94
- PETS 16.13
About XFOR X4 Pharmaceuticals Inc.
X4 Pharmaceuticals Inc is a biopharmaceutical company developing and commercializing novel therapeutics for the treatment of rare diseases of the immune system. The Company's lead clinical candidate is mavorixafor, a small molecule antagonist of the chemokine receptor CXCR4 that is being developed as an oral, once-daily therapy. It can increase the mobilization of mature, functional white blood cells from the bone marrow into the bloodstream. It also has two pre-clinical candidates X4P-003 and X4P-002 which are CXCR4 antagonists with different properties.
About PETS PetMed Express Inc.
PetMed Express Inc along with its subsidiaries is a nationwide pet pharmacy. The company markets prescription and non-prescription pet medications, health products, and supplies for dogs and cats, direct to the consumer. The company generates its revenue by selling pet medications and pet supplies mainly to retail consumers.